Document is current
Any future updates will be listed below
-
Authors
Migliarese, Christian
Sadeh, Yinon
Torrini, Consuelo
Turna Demir, Fatma
Nayyar, Naema
Yamazawa, Erika
Ishikawa, Yuu
Ijad, Nazanin
Summers, Elizabeth J.
Elliott, Adam
Rahbaek, Lisa
Saechao, Barbara
Hallin, Jill
Brastianos, Priscilla K.
Wakimoto, Hiroaki https://orcid.org/0000-0001-8225-241X
-
Funding
Funding for this research was provided by:
Mirati Therapeutics
NIH (5R01CA227156-02)
Damon Runyon Cancer Research Foundation
Ben and Catherine Ivy Foundation
- License Information
-
More Information
Article History
Received: 29 October 2024
Accepted: 1 April 2025
First Online: 2 May 2025
Change Date: 9 November 2025
Change Type: Update
Change Details: The original online version of this article was revised: The Funding information was missing and should have read ‘C.T. was supported by NIH funding (2T32HG010464-06) for the Mass General Brigham T32 Training Program’.
Declarations
:
: Not applicable.
: Not applicable.
: PKB has consulted for Atavistik, CraniUS, Eli Lilly, Genentech, InCephalo, Kazia, ACI, Angiochem, Axiom, Dantari, Elevatebio, Merck, MPM, Pfizer, Sintetica, SK Life Sciences, Tesaro, and Voyager, serves on the scientific advisory board for CraniUS and Kazia, and has received grant funding (to MGH) from Merck, Eli Lilly, Kinnate and Mirati. F.T.D. was supported by the 2219 International Postdoctoral Research Fellowship Program from the Scientific and Technological Research Council of Turkey (TÜBİTAK), Ankara, Turkey.
